First-in-Human Clinical Trials — What We Can Learn from Tragic Failures
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
On January 10, 2016, a healthy volunteer who had received 50 mg per day of a fatty acid amide hydrolase (FAAH) inhibitor for 5 days as part of a first-in-human phase 1 clinical trial was admitted to Rennes University Hospital with neurologic and gait disturbances. After a dramatic worsening of neurologic symptoms, the participant died on January 17. Another 5 participants who received the same drug dose for 6 days were subsequently admitted to the hospital, 4 of them with similar neurologic symptoms. In this issue of the Journal, Kerbrat et al.1 report the clinical and imaging findings of the . . .
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Despite strong public appeal from both clinical researchers [9,10] and regulators [11], the pharmacokinetic (PK), pharmacodynamic (PD) and clinical data obtained in the SAD and MAD studies have not been published, and many questions regarding the preclinical characteristics of the compound remain unanswered.”
Citations
Cites
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164
Assessing the Gold Standard — Lessons from the History of RCTs
Bothwell, L. E., Greene, J. A., Podolsky, S. H., & Jones, D. S. (2016) · New England Journal of Medicine · doi:10.1056/nejmms1604593 · Cited by 664
Longo, D. L., & Drazen, J. M. (2016) · New England Journal of Medicine · doi:10.1056/nejme1516564 · Cited by 419
Sharing Clinical Trial Data — A Proposal from the International Committee of Medical Journal Editors
Taichman, D. B., Backus, J., Baethge, C., Bauchner, H., de Leeuw, P. W., Drazen, J. M., Fletcher, J., Frizelle, F. A., Groves, T., Haileamlak, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejme1515172 · Cited by 190
Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase
Kerbrat, A., Ferré, J.-C., Fillatre, P., Ronzière, T., Vannier, S., Carsin-Nicol, B., Lavoué, S., Vérin, M., Gauvrit, J.-Y., Le Tulzo, Y., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604221 · Cited by 171
Transparency and the European Medicines Agency — Sharing of Clinical Trial Data
Bonini, S., Eichler, H.-G., Wathion, N., & Rasi, G. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1409464 · Cited by 82
Self-citationScientists in the dark after French clinical trial proves fatal
Butler, D., & Callaway, E. (2016) · Nature · doi:10.1038/nature.2016.19189 · Cited by 80
The EMEA Guideline on First-in-Human Clinical Trials and Its Impact on Pharmaceutical Development
Milton, M. N., & Horvath, C. J. (2009) · Toxicologic Pathology · doi:10.1177/0192623309332997 · Cited by 63
Woodcock, J., Ware, J. H., Miller, P. W., McMurray, J. J. V., Harrington, D. P., & Drazen, J. M. (2016) · New England Journal of Medicine · doi:10.1056/nejme1601510 · Cited by 20
Cited by
An evaluation framework for new approach methodologies (NAMs) for human health safety assessment
Parish, S. T., Aschner, M., Casey, W., Corvaro, M., Embry, M. R., Fitzpatrick, S., Kidd, D., Kleinstreuer, N. C., Lima, B. S., Settivari, R. S., et al. (2020) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2020.104592 · Cited by 211
Avila, A. M., Bebenek, I., Bonzo, J. A., Bourcier, T., Davis Bruno, K. L., Carlson, D. B., Dubinion, J., Elayan, I., Harrouk, W., Lee, S.-L., et al. (2020) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2020.104662 · Cited by 196
“Modification to clinical trial designs and development of more human materials-based in vitro assays has improved assessment and management of the potential for cytokine release syndrome in response to protein therapeutics (Bonini and Rasi, 2016; Grimaldi et al., 2016).”
Backgroundvan Gerven, J., & Bonelli, M. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13550 · Cited by 162
Consider drug efficacy before first-in-human trials
Kimmelman, J., & Federico, C. A. (2017) · Nature · doi:10.1038/542025a · Cited by 67
Reviewing the role of healthy volunteer studies in drug development
Karakunnel, J. J., Bui, N. Q., Palaniappan, L. P., Schmidt, K. T., Mahaffey, K. W., Morrison, B. W., Figg, W. D., & Kummar, S. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1710-5 · Cited by 55
Metadata
- Authors
- Bonini, S., & Rasi, G.
- Affiliations
- University of Rome Tor Vergata (IT)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-11-03
- Volume
- 375
- Issue
- 18
- Pages
- 1788-1789
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2547214942
- Semantic Scholar
- e9b87fab327729d49079b04f6b169d4923631246
- Cited by
- 17
- References
- 9
- Citations by year
- 2026: 1 · 2020: 3 · 2019: 2 · 2018: 3 · 2017: 7 · 2016: 1
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics in Clinical Research
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Internal Medicine › Medical Case Reports and Studies
- Keywords
- fatty acid amide hydrolase inhibitors, neurological adverse events, gait disturbance, drug-induced neurotoxicity
- MeSH terms
- Clinical Trials as Topic, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: First-in-Human Clinical Trials — What We Can Learn from Tragic Failures. https://app.cochat.ai/papers/10.1056/nejme1609006
- The paper
- Bonini, S., & Rasi, G. (2016). First-in-Human Clinical Trials — What We Can Learn from Tragic Failures. New England Journal of Medicine. https://doi.org/10.1056/nejme1609006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.